Article Information
PubMed
Print ISSN
Online ISSN
History
- Received January 10, 2012
- Accepted March 9, 2012
- Published online May 18, 2012.
Article Versions
- Earlier version (March 12, 2012 - 06:52).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2012 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Masayuki Suzuki,
- Kiyofumi Honda,
- Masanori Fukazawa,
- Kazuharu Ozawa,
- Hitoshi Hagita,
- Takahiro Kawai,
- Minako Takeda,
- Tatsuo Yata,
- Mio Kawai,
- Taku Fukuzawa,
- Takamitsu Kobayashi,
- Tsutomu Sato,
- Yoshiki Kawabe and
- Sachiya Ikeda
- Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., Gotemba, Shizuoka, Japan (M.S., K.H., M.F., K.O., T.Ka., M.T., T.F., T.Ko., T.S., Y.K., S.I.); and Chugai Research Institute for Medical Science, Inc., Gotemba, Shizuoka, Japan (H.H., T.Y., M.K.)
- Address correspondence to:
Masanori Fukazawa, Fuji Gotemba Research Laboratories, Chugai Pharmaceutical Co., Ltd., 1-135 Komakado, Gotemba, Shizuoka 412-8513, Japan. E-mail: fukazawamsn{at}chugai-pharm.co.jp
Part of this work was previously presented as follows: Suzuki M, Honda K, Fukazawa M, Ozawa K, Hagita H, Kawai T, and Ikeda S (2011) Tofogliflozin, a novel, potent, and highly selective SGLT2 inhibitor, improves glycemic control in diabetic mice and rats. 71st Scientific Sessions of the American Diabetic Association; 2011 June 24–28; San Diego, CA; pp 1136-P.